Zenas BioPharma (NASDAQ:ZBIO) Director Patricia Allen Acquires 4,160 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Patricia Allen bought 4,160 shares of the stock in a transaction dated Friday, February 13th. The shares were acquired at an average price of $26.36 per share, with a total value of $109,657.60. Following the completion of the purchase, the director directly owned 19,860 shares of the company’s stock, valued at approximately $523,509.60. This represents a 26.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Zenas BioPharma Trading Up 1.1%

NASDAQ:ZBIO opened at $26.40 on Friday. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50. Zenas BioPharma, Inc. has a one year low of $6.11 and a one year high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The business’s 50-day simple moving average is $27.56 and its 200 day simple moving average is $25.58.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Analyst Ratings Changes

Several research firms recently issued reports on ZBIO. Evercore started coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Wedbush reaffirmed an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a research report on Monday, December 22nd. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $37.00 to $19.00 in a research note on Monday, January 5th. Finally, Wall Street Zen lowered Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Institutional Investors Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its holdings in Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after acquiring an additional 2,679 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Zenas BioPharma by 13.9% in the 2nd quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after purchasing an additional 1,607 shares during the last quarter. Rhumbline Advisers boosted its position in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the period. Finally, Federated Hermes Inc. grew its stake in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after buying an additional 703,838 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.